Advertisement

Topics

RegeneRx Biopharmaceuticals, Inc. Company Profile

03:39 EDT 26th September 2018 | BioPortfolio

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. Currently RegeneRx has three products in clinical development. RGN-352 is an injectable formulation to treat cardiovascular and central nervous system diseases, as well as other medical indications. RegeneRx has successfully completed a Phase 1 clinical trial with RGN-352. RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications. RegeneRx is currently supporting a physician-sponsored Phase 2 dry eye study evaluating RGN-259. RGN-137, a topical gel formulation, is currently being evaluated by RegeneRx in a Phase 2 clinical trial for the treatment of epidermolysis bullosa. Other potential uses for RGN-137 include the treatment of chronic dermal wounds and reduction of scar tissue. Based on strong efficacy data in pre-clinical studies, RegeneRx is initially targeting RGN-352 for the treatment of patients who have suffered an acute myocardial infarction, or heart attack. In addition to this indication, recent pre-clinical efficacy data suggests that RGN-352 may also benefit patients with multiple sclerosis and stroke. RegeneRx also has a preclinical product candidate, RGN-457, which is an inhaled formulation targeting cystic fibrosis and other pulmonary diseases. In addition to the four pharmaceutical product candidates described above, RegeneRx is pursuing the commercial development of peptide fragments of Tβ4 for potential cosmeceutical use. RegeneRx holds 75 issued patents and has 261 patent applications pending worldwide related to its products and holds an exclusive worldwide license for Tβ4 from the National Institutes of Health.


News Articles [206 Associated News Articles listed on BioPortfolio]

Notice of allowance for patent on corneal wound treatment issued to RegeneRx

RegeneRx Biopharmaceuticals has been issued a notice of allowance by the U.S. Patent and Trademark Office for a new patent for treating corneal wounds using thymosin beta 4 or related therapeutic pept...

FDA requires third phase 3 trial of dry eye treatment candidate RGN-259

The FDA has accepted all safety data from two phase 3 trials of dry eye treatment candidate RGN-259, but it is requiring an additional phase 3 trial to further demonstrate efficacy, RegeneRx Biopharma...

RegeneRx Biopharmaceuticals Inc RGRX Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryRegeneRx Biopharmaceuticals Inc RegeneRx is a biopharmaceutical company that provides clinical stage drug development solutions. The company offers clinical trials, science and discovery and bu...

Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene's Virus-Based Immunotherapies TG6002 and TG1050 in Greater China

Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares Deals give Tasly Biopharmaceuticals full control over Greater China1 development and commercial rights to the...

Akebia Therapeutics to merge with Keryx Biopharmaceuticals

US-based biopharmaceutical firm Akebia Therapeutics has signed a definitive agreement to merge with Keryx Biopharmaceuticals to form a fully integrated...Read More... The post Akebia Therapeutics to m...

Eiger BioPharmaceuticals completes enrolment in Prevent trial

Eiger BioPharmaceuticals has completed patient enrolment in the Phase ll Prevent trial evaluating the safety and durability of subcutaneous (SC)...Read More... The post Eiger BioPharmaceuticals comple...

RegeneRx Biopharmaceuticals Inc RGRX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14032018] Prices from USD $250

SummaryRegeneRx Biopharmaceuticals Inc RegeneRx is a biopharmaceutical company that provides clinical stage drug development solutions. The company offers clinical trials, science and discovery and bu...

5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmaceuticals Leads with 81.62 Percent

Eiger BioPharmaceuticals, Arqule, Galectin Therapeutics, MEI Pharma and BioDelivery Sciences were last week's top gainers on the NASDAQ. The post 5 Top Weekly NASDAQ Biotech Stocks: Eiger BioPharmace...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Thrombin human [Ethicon, Inc]

These highlights do not include all the information needed to use EVITHROM safely and effectively. See full prescribing information for EVITHROM.EVITHROM, Thrombin, Topical (Human)For Topical Use Only...

PubMed Articles [38 Associated PubMed Articles listed on BioPortfolio]

Surfactants as Stabilizers for Biopharmaceuticals: An Insight into the Molecular Mechanisms for Inhibition of Protein Aggregation.

Surfactants are common stabilizers, often added to biopharmaceuticals formulations, but the mechanisms at the basis of their activity are unclear. The aim of this work is to provide insight into the m...

Next Generation Biopharmaceuticals: Product Development.

Therapeutic proteins show a rapid market growth. The relatively young biotech industry already represents 20 % of the total global pharma market. The biotech industry environment has traditionally bee...

Characterisation of protein aggregation with the Smoluchowski coagulation approach for use in biopharmaceuticals.

Protein aggregation is a field of increasing importance in the biopharmaceutical industry. Aggregated particles decrease the effectiveness of the drug and are associated with other risks, such as incr...

Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection.

Physicochemical and structural properties of proteins used as active pharmaceutical ingredients of biopharmaceuticals are determinant to carry out their biological activity. In this regard, the assays...

Harnessing the power of an expanded genetic code toward next-generation biopharmaceuticals.

Synthetic biology has been revolutionizing the biopharmaceutical industry from drug discovery, clinical development to the manufacturing of biopharmaceuticals. As one of its most promising areas, gene...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Nicotine Vaccination and Nicotinic Receptor Occupancy

This is a molecular imaging research study designed to examine how much nicotine gets into the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi Biopharm...

A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine

Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children. In China, The overall impact of Hib-related infect...

Companies [187 Associated Companies listed on BioPortfolio]

RegeneRx Biopharmaceuticals, Inc. and Lee’s Pharmaceutical Holdings Ltd.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug...

RegeneRx Pharmaceuticals, Inc.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug...

RegeneRx Biopharmaceuticals Inc.

RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-13...

RegeneRx Biopharmaceuticals

RegeneRx is a publicly-traded biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Our stock is traded on the American Stock Exc...

RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. Currently RegeneRx ...

More Information about "RegeneRx Biopharmaceuticals, Inc." on BioPortfolio

We have published hundreds of RegeneRx Biopharmaceuticals, Inc. news stories on BioPortfolio along with dozens of RegeneRx Biopharmaceuticals, Inc. Clinical Trials and PubMed Articles about RegeneRx Biopharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of RegeneRx Biopharmaceuticals, Inc. Companies in our database. You can also find out about relevant RegeneRx Biopharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record